Alnylam Pharmaceuticals (ALNY) returns
Alnylam Pharmaceuticals returns over 10 years
$1,000 invested in Alnylam Pharmaceuticals ten years ago was worth $4,540 at the close on October 30, 2026, with dividends reinvested: an average return of 16.3% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -33.1% | — | $668.72 | -0.9% |
| 3 months | -19.7% | — | $803.00 | +2.1% |
| Year to date | -58.5% | — | $414.94 | +11.7% |
| 1 year | -63.3% | — | $367.03 | +12.4% |
| 3 years | +9.0% | +2.9% | $1,090 | +88.5% |
| 5 years | +3.4% | +0.7% | $1,034 | +76.0% |
| 10 years | +354.0% | +16.3% | $4,540 | +316.6% |
Alnylam Pharmaceuticals return by calendar year
| Year | ALNY | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -58.5% | +11.7% | -70.2% |
| 2025 | +69.0% | +17.7% | +51.3% |
| 2024 | +22.9% | +24.9% | -1.9% |
| 2023 | -19.5% | +26.2% | -45.6% |
| 2022 | +40.1% | -18.2% | +58.3% |
| 2021 | +30.5% | +28.7% | +1.7% |
| 2020 | +12.9% | +18.4% | -5.5% |
| 2019 | +58.0% | +31.2% | +26.7% |
| 2018 | -42.6% | -4.6% | -38.1% |
| 2017 | +239.3% | +21.7% | +217.6% |
| 2016 | -60.2% | +12.0% | -72.2% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: ALNY financials · ALNY valuation
No forecast, no recommendation. This page describes Alnylam Pharmaceuticals from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.